Comparison of Non-Vitamin K Antagonist Oral Anticoagulants on Ischemic Stroke and Bleeding

Betül Özenç, O. Kurşun
{"title":"Comparison of Non-Vitamin K Antagonist Oral Anticoagulants on Ischemic Stroke and Bleeding","authors":"Betül Özenç, O. Kurşun","doi":"10.36472/msd.v10i12.1097","DOIUrl":null,"url":null,"abstract":"Objective: Non-vitamin K antagonist oral anticoagulants (NOACs) have become widely utilized for various clinical indications, including non-valvular atrial fibrillation (NVAF), deep vein thrombosis (DVT), and apical thrombus. Despite their increasing popularity, limited comparative data exist on the clinical outcomes associated with different NOACs. This study aims to address this gap by directly comparing NOACs in terms of ischemic stroke, hemorrhagic stroke, and gastrointestinal bleeding.\nMaterials and Methods: A retrospective search of the electronic database was conducted to identify patients using NOACs for NVAF, DVT, and apical thrombus. Clinical outcomes, including ischemic stroke, hemorrhagic stroke, and gastrointestinal bleeding, were directly compared among different NOACs. The chi-square test and Fisher's exact test were employed to assess the relative incidence of stroke and extracranial complications across four patient groups.\nResults: Among the 4,112 retrospectively analyzed patients, 55 were included in the study. Demographic and clinical profiles showed no significant differences among patients in the four different drug groups (p > 0.05). Ischemic stroke was observed in 90.9% of the patients, hemorrhagic stroke in 5.8%, and gastrointestinal bleeding in 3.3%. A statistically significant difference was identified between drug doses and the rate of ischemic stroke (p < 0.001).\nConclusion: The findings of this retrospective study carry significant implications, especially considering the widespread global use of NOACs. The study revealed no discernible difference in the risk of ischemic stroke among patients using different NOACs. Notably, the risk of hemorrhagic stroke was dose-dependent in the dabigatran group, while rivaroxaban was associated with the highest risk of gastrointestinal bleeding. Given the elevated rate of thromboembolism in patients and the relatively short half-life of NOACs, the study concludes that further optimization of NOAC use is imperative.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Science and Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36472/msd.v10i12.1097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Non-vitamin K antagonist oral anticoagulants (NOACs) have become widely utilized for various clinical indications, including non-valvular atrial fibrillation (NVAF), deep vein thrombosis (DVT), and apical thrombus. Despite their increasing popularity, limited comparative data exist on the clinical outcomes associated with different NOACs. This study aims to address this gap by directly comparing NOACs in terms of ischemic stroke, hemorrhagic stroke, and gastrointestinal bleeding. Materials and Methods: A retrospective search of the electronic database was conducted to identify patients using NOACs for NVAF, DVT, and apical thrombus. Clinical outcomes, including ischemic stroke, hemorrhagic stroke, and gastrointestinal bleeding, were directly compared among different NOACs. The chi-square test and Fisher's exact test were employed to assess the relative incidence of stroke and extracranial complications across four patient groups. Results: Among the 4,112 retrospectively analyzed patients, 55 were included in the study. Demographic and clinical profiles showed no significant differences among patients in the four different drug groups (p > 0.05). Ischemic stroke was observed in 90.9% of the patients, hemorrhagic stroke in 5.8%, and gastrointestinal bleeding in 3.3%. A statistically significant difference was identified between drug doses and the rate of ischemic stroke (p < 0.001). Conclusion: The findings of this retrospective study carry significant implications, especially considering the widespread global use of NOACs. The study revealed no discernible difference in the risk of ischemic stroke among patients using different NOACs. Notably, the risk of hemorrhagic stroke was dose-dependent in the dabigatran group, while rivaroxaban was associated with the highest risk of gastrointestinal bleeding. Given the elevated rate of thromboembolism in patients and the relatively short half-life of NOACs, the study concludes that further optimization of NOAC use is imperative.
非维生素 K 拮抗剂口服抗凝药对缺血性中风和出血的影响比较
目的:非维生素K拮抗剂口服抗凝剂(NOACs)已广泛应用于各种临床适应症,包括非瓣膜性心房颤动(NVAF)、深静脉血栓(DVT)和根尖血栓。尽管它们越来越受欢迎,但与不同noac相关的临床结果的比较数据有限。本研究旨在通过直接比较noac在缺血性卒中、出血性卒中和胃肠道出血方面的差异来解决这一差距。材料和方法:对电子数据库进行回顾性检索,以确定使用NOACs治疗非瓣膜性房颤、DVT和根尖血栓的患者。临床结果,包括缺血性卒中、出血性卒中和胃肠道出血,直接比较不同noac之间的差异。采用卡方检验和Fisher精确检验来评估四组患者脑卒中和颅外并发症的相对发生率。结果:在回顾性分析的4112例患者中,有55例纳入研究。不同用药组患者的人口学及临床资料差异无统计学意义(p > 0.05)。缺血性脑卒中占90.9%,出血性脑卒中占5.8%,胃肠道出血占3.3%。药物剂量与缺血性卒中发生率之间存在统计学差异(p < 0.001)。结论:这项回顾性研究的结果具有重要意义,特别是考虑到NOACs在全球的广泛使用。研究显示,使用不同noac的患者发生缺血性卒中的风险没有明显差异。值得注意的是,出血性中风的风险在达比加群组是剂量依赖性的,而利伐沙班与胃肠道出血的风险最高相关。鉴于患者血栓栓塞率升高以及NOAC的半衰期相对较短,该研究得出结论,进一步优化NOAC的使用势在必行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信